Automatically clustered newsroom coverage around one of the most active themes in the intellectual property ecosystem.
The US Supreme Court has granted certiorari to hear a patent infringement case centered on the 'skinny label' strategy employed by generic drug manufacturers, involving Amarin Pharma. The case will address whether a generic drug maker can be held liable for inducing infringement when its product is labeled for non-pat…
On January 16, 2026, the U.S. Supreme Court granted certiorari to review a Federal Circuit ruling in Hikma Pharmaceuticals USA v. Amarin Pharma. The case centers on whether generic drug makers who exclude patented uses from their product labels—so-called 'skinny labels'—can still face patent infringement claims based…
Subscribe to receive daily and weekly newsroom coverage aligned to this trend cluster and adjacent IP developments.